Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roundhill GLP-1 & Weight Loss ETF (NQ:OZEM)

30.09 +0.02 (+0.05%)
Streaming Delayed Price Updated: 12:14 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roundhill GLP-1 & Weight Loss ETF

News headline image
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector. 
Via Stocktwits
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products. 
Via Stocktwits
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
Via Stocktwits
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease. 
Via Stocktwits
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month. 
Via Stocktwits
Topics Intellectual Property
Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today ↗
Via Stocktwits
News headline image
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is... 
Via Stocktwits
Topics Intellectual Property
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
Are You Making These 3 ETF Mistakes That Cost You 50% in Gains? ↗
Exchange-traded funds are great long-term investments, but you have to think about them in the right way. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat ↗
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
News headline image
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish ↗
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity. 
Via Stocktwits
Topics Earnings
News headline image
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections ↗
The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches. 
Via Stocktwits
Topics Earnings
News headline image
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
News headline image
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk ↗
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
News headline image
Tesla (TSLA) Stock Drops as Glass Lewis Urges Against Elon Musk’s Pay Package ↗
Tesla stock is down on Tuesday as advisory firm Glass Lewis recommends TSLA shareholders vote against a massive pay package for Elon Musk. 
Via InvestorPlace
News headline image
Campbell Soup Layoffs 2024: What to Know About New Campbell Job Cuts ↗
Campbell Soup layoffs are coming for 415 workers as the company plans to close down one factory and shift operations at others. 
Via InvestorPlace
Topics Workforce
News headline image
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF ↗
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
News headline image
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next ↗
Weight loss drugs get the new parody treatment in a "South Park" streaming special. 
Via Benzinga
Topics Artificial Intelligence
News headline image
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic ↗
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.